Biosergen Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Private

  • Employees
  • 1

Employees

  • Latest Deal Type
  • Buyout/​LBO

Biosergen General Information

Description

Biosergen AB is a clinical-stage biotechnology company advancing the treatment of life-threatening fungal infections. It has developed the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 is a drug in the field of antifungals because of its fungicidal effect (it kills the fungus), which is preferable to drugs with a fungistatic effect.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Fogdevreten 2
  • 171 65 Solna
  • Sweden
+46
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Fogdevreten 2
  • 171 65 Solna
  • Sweden
+46

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biosergen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Buyout/LBO 26-Jun-2026 Completed Generating Revenue
5. PIPE 03-May-2024 Completed Generating Revenue
4. IPO 24-Jun-2021 Completed Generating Revenue
3. Grant 01-Dec-2019 Completed Generating Revenue
2. Later Stage VC 13-Feb-2013 Completed Generating Revenue
1. Early Stage VC Completed Startup
To view Biosergen’s complete valuation and funding history, request access »

Biosergen Patents

Biosergen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025253319-A1 Polyene macrolide for use in methods for treatment of fungal infections Pending 05-Jun-2024
WO-2025172861-A2 Compositions of a therapeutic polyene macrolide and methods of their use Pending 14-Feb-2024
WO-2025172861-A3 Compositions of a therapeutic polyene macrolide and methods of their use Pending 14-Feb-2024
WO-2025172860-A1 Polyene macrolide compositions and uses thereof Pending 14-Feb-2024
CA-3172776-A1 Pharmaceutical compositions of a therapeutic polyene macrolide and methods of their use Pending 26-Feb-2020 A61K31/7048
To view Biosergen’s complete patent history, request access »

Biosergen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biosergen ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Biosergen’s complete esg history, request access »

Biosergen FAQs

  • When was Biosergen founded?

    Biosergen was founded in 2004.

  • Where is Biosergen headquartered?

    Biosergen is headquartered in Solna, Sweden.

  • What is the size of Biosergen?

    Biosergen has 1 total employees.

  • What industry is Biosergen in?

    Biosergen’s primary industry is Drug Discovery.

  • Is Biosergen a private or public company?

    Biosergen is a Private company.

  • What is Biosergen’s current revenue?

    The current revenue for Biosergen is .

  • How much funding has Biosergen raised over time?

    Biosergen has raised $5.98M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process